TEST:

NOVOPM panel

The Novogene Precision Medicine 2.0 (NovoPM™ 2.0) comprehensive genomic profiling test for solid tumors is a hyphenate sequencing (NGS)-based assay that analyzes 484 genes for clinically important alterations at the DNA level. These genes are known to be relevant for the diagnosis and/or treatment of various solid tumors according to National Comprehensive Cancer Network (NCCN) Guidelines and the medical literature. All tests are performed in our CAP-accredited lab and analyzed by our in-house bioinformatics specialists. Report generated provides tailored treatment recommendations for your patients.